Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag in Children With Pulmonary Arterial Hypertension
NCT03492177Phase 2Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2018; status: active, not recruiting.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03492177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492177.